DAN Stock Recent News

MAUMEE, Ohio , July 16, 2024 /PRNewswire/ -- Dana Incorporated (NYSE: DAN) will release its 2024 second-quarter financial results on Wednesday, July 31, 2024. A press release will be issued at approximately 7 a.m.

MAUMEE, Ohio , July 16, 2024 /PRNewswire/ -- Dana Incorporated (NYSE: DAN) today announced the appointment of Brian Pour as Senior Vice President and President of Dana Commercial Vehicle Drive and Motion Systems, effective July 22. Mr. Pour succeeds Aziz Aghili, who recently retired from Dana.

MAUMEE, Ohio , June 26, 2024 /PRNewswire/ -- Dana Incorporated (NYSE: DAN) today announced the appointment of Dana veteran Lisa Amend as Senior Vice President and Chief Human Resources Officer. Ms. Amend brings to this role more than 20 years of experience as a labor and employment attorney supporting human resources in all areas, including litigation and dispute management, labor relations, employee benefits, and executive compensation.

THE WOODLANDS, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- Howard Hughes Holdings Inc. (NYSE: HHH) announced today the appointment of Dana Hamilton to the company's Board of Directors. Ms. Hamilton is a veteran C-suite executive with a track record of growing successful real estate operating and investment companies and using data analytics and technology to drive performance-enhancing organizational and industry change.

Dana Incorporated's share price has underperformed the broader market, but the company's revenue and cash flows have been generally positive. The company's revenue increased by 3.9% in the last fiscal year, driven by organic growth in Europe and light truck and medium/heavy truck production. Despite some weaknesses in profitability, management remains optimistic about the company's future and expects revenue and EBITDA to increase in the next fiscal year.

We believe that currently, one should keep a tab on stocks like American Public Education (APEI), Bread Financial (BFH), Warner Bros. Discovery (WBD), Dana Incorporated (DAN) and eXp World (EXPI).

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a collaboration to conduct an investigator-sponsored trial (IST) evaluating zotatifin in combination with abemaciclib and letrozole in patients with estrogen receptor-positive (ER+) endometrial cancer and low grade serous ovarian cancer at the Dana-Farber Cancer Institute (DFCI) under the direction of Panagiotis Konstantinopoulos, M.D., Ph.D., Director of Translational Research and attending oncologist in the Division of Gynecologic Oncology at DFCI, and an Associate Professor of Medicine at Harvard Medical School.

Although the revenue and EPS for Dana (DAN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Dana (DAN) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.25 per share a year ago.

The headline numbers for Dana (DAN) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.